Berberine: chemical, pharmacological aspects and its potential prophylactic relationship with Alzheimer's disease

Authors

DOI:

https://doi.org/10.33448/rsd-v12i4.41313

Keywords:

Alzheimer´s disease; Berberine; Chemistry of natural products; Therapy.

Abstract

This article aimed to review the chemical and pharmacological aspects of berberine, correlating them with the pathophysiological outcome of Alzheimer's disease (AD). A descriptive study of the narrative literature review type was carried out. The investigative locus was carried out through an electronic search in the Scientific Electronic Library (SciELO), Latin American and Caribbean Center on Health Sciences Information (BIREME-PAHO-WHO) and National Library of Medicine, USA (PubMed), being Articles published between 2018 and 2023 in English, Portuguese and Spanish were considered. The search for articles was based on the search for the keywords berberine and Alzheimer's disease, using the Boolean operator and to connect these terms. Berberine is classified as a quaternary ammonium salt, it is part of the group of isoquinoline alkaloids called protoberberine. Some studies indicate that berberine is able to attenuate the inflammatory process, excitotoxicity, excessive activity of free radicals and deposition of senile plaques. This review summarized the chemical and physical-chemical aspects of berberine, relating them to bioavailability parameters; clarified some points of the etiology, pathophysiology and clinical manifestations of Alzheimer's disease, considering its complexity; and correlated them considering the main action switches of the neuroprotective substance. In vivo and in vitro studies demonstrate that berberine has therapeutic potential for the treatment of Alzheimer's disease. However, it is still not possible to state whether these results are translational. To verify its effectiveness in humans and estimate possible therapeutic doses, if necessary, robust clinical studies.

References

Ai, X., Yu, P., Peng, L., Luo, L., Liu, J., Li, S., ... & Meng, X. (2021). Berberine: A review of its pharmacokinetics properties and therapeutic potentials in diverse vascular diseases. Frontiers in Pharmacology, 3104.

Akbar, M., Shabbir, A., Rehman, K., Akash, M. S. H., & Shah, M. A. (2021). Neuroprotective potential of berberine in modulating Alzheimer’s disease via multiple signaling pathways. Journal of Food Biochemistry, 45(10), e13936.

Brucki, S. M. D., Aprahamian, I., Borelli, W. V., Silveira, V. C. D., Ferretti, C. E. D. L., Smid, J., ... & Morillo, L. S. (2022). Manejo das demências em fase avançada: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia & Neuropsychologia, 16, 101-120.

Chaves, J. C., Toledo, P. D., Rodrigues Filho, M., & ML, M. F. (2018). Tratamento farmacológico e assistência psicológica na Doença de Alzheimer. Revista Saúde em Foco, 10, 963-973.

Chen Y, Chen Y, Liang Y, Chen H, Ji X, & Huang M. (2020). Berberine mitigates cognitive decline in an Alzheimer's Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed Pharmacother. 121:109670.

Chen, C., Liu, Q., Dong, M., Sun, B., Tao, X., Wang, Y., & Li, Y. (2019). Anti-inflammatory effects of berberine on the microbiome and gut-liver axis in high-fat diet-fed mice. Frontiers in Physiology, 10, 1438.

Cheng Z, Kang C, Che S, Su J, Sun Q, Ge T, Guo Y, Lv J, Sun Z, Yang W, Li B, Li X, Cui R. & Berberine: A (2022). Promising Treatment for Neurodegenerative Diseases. Front Pharmacol. 13:845591.

Cushnie, T. P. T., & Lamb, A. J. (2017). Recent advances in understanding the antibacterial properties of flavonoids. International Journal of Antimicrobial Agents, 49(4), 401-408.

DeMarshall, C A. et al. (2023). 'Detecção Precoce de Patologia Relacionada à Doença de Alzheimer Usando uma Plataforma de Diagnóstico Multi-Doença Empregando Autoanticorpos como Biomarcadores Baseados no Sangue'. 1 a 15.

Eratne, D., Loi, S. M., Farrand, S., Kelso, W., Velakoulis, D., & Looi, J. C. (2018). Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 26(4), 347–357.

Freire, D. S., da Silva, A. S., & Borin, F. Y. Y. (2022). A fisiopatologia da doença de alzheimer. Revista Terra & Cultura: Cadernos de Ensino e Pesquisa, 38(especial), 237-251.

Galende, A. V., Ortiz, M. E., Velasco, S. L., Luque, M. L., de Miguel, C. L. D. S., & Jurczynska, C. P. (2021). Informe de la Fundación del Cerebro. Impacto social de la enfermedad de Alzheimer y otras demencias. Neurología, 36(1), 39-49.

Garre-Olmo, J. (2018). Epidemiología de la enfermedad de Alzheimer y otras demencias. Rev Neurol, 66(11), 377-386.

Imenshahidi M, & Hosseinzadeh H. (2019). Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 33(3):504-523.

Janelidze, S., Mattsson, N., Palmqvist, S. et al. (2020). Plasma P-tau181 na doença de Alzheimer: relação com outros biomarcadores, diagnóstico diferencial, neuropatologia e progressão longitudinal para a demência de Alzheimer. Nat Med 26, 379–386

Kumar, A., Sidhu, J., Goyal, A., & Tsao, J. W. (2022). Alzheimer Disease. In StatPearls. StatPearls Publishing.

Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer's disease. European journal of neurology, 25(1), 59-70.

Li, Y., Zhao, S., Zhang, W., Zhao, G., & Wang, J. (2017). A associação entre consumo de berberina e doença cardiovascular: uma revisão sistemática e meta-análise de ensaios clínicos randomizados. Planta Medica, 83(5), 385-393.

Machado, A. P. R., Carvalho, I. O., & da Rocha Sobrinho, H. M. (2020). Neuroinflamação na doença de Alzheimer. Revista brasileira militar de ciências, 6(14).

Machado, N. N., Faria, J. M., Martins, J. L., & de Moraes, M. B. (2021). Efeitos da berberina sobre o metabolismo energético e parâmetros antropométricos em indivíduos com sobrepeso e obesidade: um ensaio clínico randomizado. Revista de Nutrição, 34, e210082

Martins M. D. F. M. (2018). Estudos de revisão de literatura. Rio de Janeiro: FIOCRUZ/ICICT:37

Maryam, R. S., Sahar, J., Hastono, S. P., & Harimurti, K. (2021). Common symptoms of Alzheimer’s dementia that are easily recognizable by families. Dementia & Neuropsychologia, 15(Dement. neuropsychol., 2021 15(2)), 186–191.

Mira, A., Gonçalves, R., & Rodrigues, I. T. (2022). Dysphagia in Alzheimer’s disease: a systematic review. Dementia & Neuropsychologia, 16(Dement. neuropsychol., 2022 16(3)), 261–269.

Nabizadeh, F., Balabandian, M., Rostami, M. R., Kankam, S. B., Ranjbaran, F., & Pourhamzeh, M., (2022). Alzheimer’s Disease Neuroimaging Initiative (ADNI). Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer’s disease: results from ADNI. Aging Clinical and Experimental Research, 34(10), 2363-2372.

Nadendla, S., & Mohiuddin, S. S. (2023). Biochemistry, Presenilin. In StatPearls. StatPearls Publishing.

Nogueira, L. R. M., Freitas, M. F. L. de, & Mello, J. R. V. de. (2021). Avaliação de placas senis e emaranhados neurofibrilares no hipocampo de indivíduos portadores de Alzheimer através da histologia e imunohistoquímica. Atena Editora.

Oliveira, T. B., Vasconcelos, C. M. L., Ferreira, M. A., & Souza, G. R. (2021). Berberina: um composto bioativo com potencial terapêutico em doenças metabólicas. Brazilian Journal of Development, 7(8), 76255-76266.

Ortiz, K. Z., de Lira, J. O., Minett, T. S. C., & Bertolucci, P. H. F. (2021). Language impairment in the moderate stage of dementia due to Alzheimer's disease. Arquivos De Neuro-psiquiatria, 79(Arq. Neuro-Psiquiatr., 2021 79(4)), 283–289.

Pedroso, R. V., Corazza, D. I., Andreatto, C. A. de A., Silva, T. M. V. da, Costa, J. L. R., & Santos-Galduróz, R. F. (2018). Cognitive, functional and physical activity impairment in elderly with Alzheimer's disease. Dementia & Neuropsychologia, 12(Dement. neuropsychol., 2018 12(1)), 28–34.

Purwaningsih I, Maksum I P, Sumiarsa D, & Sriwidodo S. A (2023). Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant. Molecules. 28(3):1294.

Ribeiro, B. M., Barbosa, M. T., & Serafini, M. R. (2021). Berberina como potencial coadjuvante no tratamento da obesidade. Revista Eletrônica de Farmácia, 18(2), 1-10.

Ribeiro, H. F., dos Santos, J. S. F., & de Souza, J. N. (2021). Doença de Alzheimer de início precoce (DAIP): características neuropatológicas e variantes genéticas associadas. Revista De Neuro-Psiquiatria, 84(2), 113-127.

Sheppard, O., & Coleman, M. (2020). Alzheimer’s disease: etiology, neuropathology and pathogenesis. Exon Publications, 1-21.

Silva, M. V. F., Loures, C. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019). Alzheimer's disease: risk factors and potentially protective measures. Journal of biomedical science, 26(1), 33.

Singh A K, Singh S K, Nandi M K, Mishra G, Maurya A, Rai A, Rai G K, Sharma A R B, & Kulkarni G T. (2019). Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease. Central Nervous System Agents in Medicinal Chemistry, 2019, 19, 1-00

Song D, Hao J, & Fan D. (2020). Biological properties and clinical applications of berberine. Front Med. 2020 Oct;14(5):564-582. 10.1007/s11684-019-0724-6.

.

Souza, E. S. de, Santos, A. M. da S., & Silva, A. de J. D. (2021). Doença de Alzheimer: abordagem sobre a Fisiopatologia. Revista Espisteme Transversalis, Volta Redonda, 12(2), 356–381.

Tailor, B., Pilozzi, A., & Huang, X. (2019). Contributing Factors of Neurodegeneration in Alzheimer’s Disease. Exon Publications, 69-84.

Tao Q Q, Lin R R, & Wu Z Y. (2023). Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era. Clin Interv Aging. 18:353-358.

Tiel, C., Sudo, F. K., & Calmon, A. B. (2019). Neuropsychiatric symptoms and executive function impairments in Alzheimer’s disease and vascular dementia: The role of subcortical circuits. Dementia & Neuropsychologia, 13(Dement. neuropsychol., 2019 13(3)), 293–298.

Vellosa, J. C. R., Biavatti, M., Françóia, P. C. O., de Mello, B. J., de Almeida, A. C., & Bueno, G. E. (2021). Estresse oxidativo: uma introdução ao estado da arte / Oxidative stress: an introduction to the state of art. Brazilian Journal of Development, 7(1), 10152–10168.

Velmurugan, B. K., Rathinasamy, B., Lohanathan, B. P., Thiyagarajan, V., & Weng, C. F. (2018). Neuroprotective role of phytochemicals. Molecules, 23(10), 2485.

Wolinsky, D., Drake, K., & Bostwick, J. (2018). Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease. Current psychiatry reports, 20(12), 117.

Wu, H., Huang, T., Ying, Y., & Zhang, H. (2018). Berberine and its derivatives: a patent review (2009 - 2018). Expert Opinion on Therapeutic Patents, 28(11), 817-831.

Wu, J., Zhang, G., & Xu, J. (2017). Antimicrobial activity of berberine alone and in combination with norfloxacin against Escherichia coli and Staphylococcus aureus. Journal of Hainan Medical University, 21(1), 11-14.

Yuan N N, Cai C Z, Wu M Y, Su H X, Li M, & Lu J H. (2019). Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies. BMC Complement Altern Med. 19(1):109.

Yun, S. M., Cho, S. J., Jo, C., Park, M. H., Han, C., & Koh, Y. H. (2020). Elevation of plasma soluble amyloid precursor protein beta in Alzheimer’s disease. Archives of Gerontology and Geriatrics, 87, 103995.

Zhang L, Wu X, Yang R, Chen F, Liao Y, Zhu Z, Wu Z, Sun X, & Wang L. (2021). Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol. 10:588517.

Downloads

Published

19/04/2023

How to Cite

FREITAS, S. R. do N. .; SILVA, T. F. da .; RODRIGUES, J. R. P. .; ARAÚJO, V. R. A. de .; RAMOS, A. A. da S. .; SILVA, I. F. da .; SILVA , N. J. da .; SOUSA, D. G. da S. .; LIMA , C. D. O. de . Berberine: chemical, pharmacological aspects and its potential prophylactic relationship with Alzheimer’s disease. Research, Society and Development, [S. l.], v. 12, n. 4, p. e27712441313, 2023. DOI: 10.33448/rsd-v12i4.41313. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/41313. Acesso em: 24 apr. 2024.

Issue

Vol. 12 No. 4

Section

Review Article

License

Copyright (c) 2023 Samuel Rodrigues do Nascimento Freitas; Thiago Filipe da Silva; Jefferson Renan Pinheiro Rodrigues; Victória Raquel Alves de Araújo; Alexsandra Andreia da Silva Ramos; Ivini Ferreira da Silva; Nataly Juliany da Silva ; Danielly Gonçalo da Silva Sousa; Caique Derwsom Oliveira de Lima

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.